ESMO 2026: Advances in NMIBC and MIBC

Share :
Published: 25 Oct 2026
Views: 1564
Rating:
Save
Dr Bernadett Szabados, Prof Andrea Necchi, Dr Félix Guerrero-Ramos and Prof Yohann Loriot

Dr Bernadett Szabados (University College London Hospital, London, UK), Prof Andrea Necchi (The Vita-Salute San Raffaele University, Milan, Italy), Dr Félix Guerrero-Ramos (Hospital Universitario 12 de Octubre, Madrid, Spain) and Prof Yohann Loriot (Gustave Roussy, Villejuif, France) discuss new data from the ESMO 2026 conference on non-muscle invasive and muscle-invasive bladder cancer.

The panel discusses updated results from the POTOMAC trial of durvalumab plus BCG in high-risk non-muscle-invasive bladder cancer, including the potential to reduce radical cystectomy rates.

In muscle-invasive bladder cancer, the experts examine findings from the ENERGIZE and KEYNOTE-866 trials.

They also discuss the VOLGA trial of enfortumab vedotin plus durvalumab, with or without tremelimumab, in cisplatin-ineligible patients, including the potential to reduce treatment-related toxicity by omitting adjuvant enfortumab vedotin.

The discussion explores emerging bladder preserving strategies, the limitations of pathological complete response as a predictor of long term outcomes, and the potential role of circulating tumour DNA in guiding treatment de-escalation.

They also explore the NIAGARA and TROPHY-U-01 trials.

Finally, the panel considers investigational combinations for metastatic disease and the challenges of balancing treatment efficacy, toxicity and quality of life.

Durvalumab (D) in Combination With BCG Induction and Maintenance (I+M) for BCG-Naïve, High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): Early Recurrence and Cystectomy-Free Survival in Patients (pts) With Papillary Only Tumours From POTOMAC
ENERGIZE and KEYNOTE-866 trials
Exploratory Analysis of Molecular Subtypes and Association With Treatment Outcomes in Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC) From NIAGARA
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
Sacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7

 

Supported by an independent educational grant from Johnson & Johnson

BS: Hi everybody, my name is Bernadett Szabados, I'm from the University of Cambridge and I'm delighted to be surrounded with my wonderful co-chairs at this e-cancer filming today. Hello, my name is Félix Guerrero-Ramos, I'm the Head of the Uro-Oncology Unit at the Department of Urology at Hospital Universitario 12 de Octubre and mainly focused on bladder cancer. I'm Andrea Necchi, I'm a Professor of Oncology at Vita Salute San Rafael University in Milan, Italy and Director of Medical Oncology in San Rafael Hospital in Milan, Italy.

YL: Hello, I'm Yohann Loriot, I'm a Medical Oncologist and Professor at Université Paris-Saclay and at Gustave Roussy, I'm Deputy Head of the Department of Phase 1 there.

BS: This has been so far an absolutely amazing ESMO, but Félix, I wanted to ask you personally, what were your highlights with regards to non-muscle invasive bladder cancer?

FGR: Well, the main highlight or the main update has been regarding the POTOMAC study. We know that POTOMAC was a positive trial for BCG-naive patients with high-risk non-muscle invasive bladder cancer with an FDA approval so far.

In this meeting, we've had updated data and we also have some numbers on relevant outcomes such as radical cystectomy and we are seeing that with the combination of durvalumab plus BCG induction and maintenance, we are achieving lower rates of radical cystectomies and we are achieving also less patients undergoing the BCG-unresponsive condition. So, in this setting of non-muscle invasive bladder cancer and with these drugs which for sure add toxicity because we are adding systemic immune checkpoint inhibition, we have to see that we have positive results in relevant endpoints. And to my opinion, I think that having less number of radical cystectomies really impacts patients' quality of life and the course of the disease.

BS: Amazing, thank you so much. And then the next highlight was really all around the muscle invasive bladder cancer space. Andrea, what were your highlights at this ESMO? We have seen multiple abstracts.

AN: Yeah, too many data already and the new fresh data coming into the ground of the discussion for patients with MIBC. We had already too many data with various combination therapies and paradigm for treatment. The entire paradigm for treatment in this patient is shifting quite rapidly in our hands and in translating quite rapidly from trials to real world.

This year, ESMO meeting provided novel data from two big phase three trials with regards to the use of chemotherapy. Two big trials, the ENERGIZE trial and the KEYNOTE-866 trial that challenged the role for immune therapy as a combination therapy with backbone cisplatin-based chemotherapy in cisplatin-eligible population. They saw the well-known 50% of the patients who were eligible to receive cisplatin.

It's interesting to see that both of these trials didn't meet the primary endpoint, the co-primary endpoints of a PCR event-free survival. And at the end, they did not result in a significant gain in overall survival. It's interesting, despite a numerical improvement, a numerically higher rates of PCR, ranging between 35% to 40% with a combination of chemo immune therapy, despite not meeting the primary endpoint, it's interesting when merging the data and when including the NIAGARA trial, which is still the standard of care in Europe.

Overall, this data are practise informing in the way we will conceive tomorrow or on Tuesday after the closure of the ESMO meeting, the role of chemotherapy and the patient counselling with regards to the possibility to get chemotherapy or chemotherapy-based combination that will become, in my opinion, very hard to pursue, in particular based on the data that are emerging from different possibilities for treatment like ADC-IO combination.

YL: And does this data change your opinions on the chemo-IO and specifically NIAGARA? Because we have one positive trial, two negative trials. It's very difficult to know why NIAGARA is positive and the ENERGIZE and 866 are negative because pretty the same population, same concepts. So, do you think that the level of evidence should be lower on chemo-IO?

AN: Well, it's difficult in principle to compare the studies because they accrue different patient population. It is possible that the checkpoint inhibitors are not interchangeable. So, nivolumab is not the same as pembrolizumab.

I guess that people, most of the investigators, most of the physicians, were already concerned about using chemotherapy in this patient population. And there is a sizeable population or increasing population of patients who are already refusing chemotherapy, splatting chemotherapy in this field. So, it is not actually a big shifting ground.

It's just the phase three data corroborating uncertainties with regards to the use of chemotherapy that were already there, even with chemotherapy or chemo-immuno therapy combination as being the standard of care. We were very much concerned about multiple things, toxicity, marginal improvements in the outcomes already. So, we know already that splitting chemotherapy didn't get the chance for most of the patients to be cured by avoiding side effects or avoiding, maybe in the future, major surgery and so.

So, the possibility to shift completely the paradigm towards something completely different was seen by the patient side as a big possibility in general. So, the phase three data ENERGIZE and the KEYNOTE 866 just corroborate our already existing impression related to the use of chemotherapy.

YL: I think it's still important to run different phase three trials when we have big questions, very relevant questions, because maybe NIAGARA could be positive by chance, actually. So, it's very important that we run multiple phase three trials for the same questions, I think.

BS: And Yoann, I wanted to ask you your opinion about the VOLGA trial and specifically in comparison with 905.

YL: So, the VOLGA trial also addresses different concepts. So, here, it is a combination of an ADC, so, enfortumab vedotin, and immunotherapy. So, very similar approach compared to B15 and 905. So, B15 compared EV pembro versus chemotherapy in CIS-eligible patients and 905 compared to EV pembro followed by surgery, followed by IO-driven phases versus cystectomy up front.

So, here, VOLGA focused on patients who were deemed ineligible to cisplatin-based chemotherapy. And the concept was to give, so, durvalumab combined with EV or EV combined durvalumab and tremelimumab followed by surgery versus surgery alone. And so, the data are very similar to what we have seen in 905. So, the combination of duvalumab and EV improve EFS, improve overall survival. The big difference between 905, B15, and VOLGA, that there is no eye-driven phases for EV. So, we maintain durvalumab, but there is no IO-driven phases.

I think it's an important different concept compared to, it's like optimisations of the EV pembro-like regimen. So, it's changed the practise because I guess that for the physicians who have access to EV-P, not in Europe yet, except in Germany, for example, but for the physicians who have access to EV-P, probably many of them will maybe restrict the EV pembro combination to the neoadjuvant phases and maybe not for the eye-driven phases. So, it's a very important difference between the two trials.

BS: What do you think about the peripheral neuropathy differences?

YL: Yeah, so it is explained mainly by the fact that the patient did not receive EV for the IO-driven phases. So, usually the neuropathy occurs after five, six months. So, obviously, during the neoadjuvant phases, very few patients develop neuropathy.

So, the main part of the neuropathy occurs in the IO-driven phases. So, that's why there is a clear difference between 905 and VOLGA.

AN: And do you expect that the lower rate of PCR, the 44% PCR rate with the durva and EV as compared to 57% with the pembro EV, do you think that that could be a problem when discussing with the patient opportunities? Maybe if a patient comes to you at your table and says, okay, let's start with systemic therapy. But do you already know that they still may be interested in a kind of bladder preservation or newer opportunities that may come depending on the response? Would you be more comfortable in using durva EV as compared to pembro EV?

YL: For the patient standpoint, I think it's not a problem because what we want is to improve PFS and overall survival. So, we have this with VOLGA and 905. I think the main problem for us, Andrea, because, of course, the next step is to do bladder preservation strategy. And everything that we did in the past were based on the PCR. And actually, what we have seen that PCR is not very reliable without for the EFS and overall survival. And, for example, in ENERGIZE and 866, PCR is more or less 40%. So, very close to what we have seen in VOLGA that EFS and overall survival were not improved actually in the chemo IOs. So, it's very difficult to rely on all the strategies that we will develop on PCR. Maybe ctDNA, of course, in the blood. It's something very important, maybe more important than the PCR. So, the clearance of the ctDNA. Maybe in urine, something important to analyse. And maybe the clinical response with MRI does matter as well. So, I think the next step for us is to develop a very robust, strong clinical response that could correlate strongly with PFS and overall survival. But PCR itself, I think it's not enough.

FGR: I agree with you that in the future, with such good outcomes with all these new systemic drugs, we will be sparing more bladders, luckily. And we will be letting our patients to preserve their bladder. As you said, something critical is the definition and the accuracy of the clinical complete response. We're not going to be able to have a pathological complete response because we're not removing the bladder. And I guess if in these patients also, once we start thinking about bladder preserving strategies, apart from the systemic therapy, should we also add some local therapy to increase the responses? And to treat not only the tumour, but the whole urothelium that we know is not a healthy urothelium really in these patients. So, my point is we have very good response rates. We don't still know in the long term how these patients are going to behave, if they're going to have NMIBC recurrences or distant recurrences or whatever. But I think it's a good opportunity to also add intravesical therapy to try to consolidate and achieve higher responses.

AN: The point to which we are very much happy to deal with, with regards to the possibility of de-escalating EV in the adjuvant part, so avoiding the extra side effects of EV, is just corroborating the need to avoid the bigger, much bigger side effects related to radical cystectomy in most of the patients. So, the possibility to de-escalate and to avoid side effects, to make a big change, and not just with the systemic therapy, but just to avoid surgical part is good. And side effects are important, I agree with you. It would be nice to see in the real world what is actually the current situation with regards to the EV administration in the EV-Pembro story. In the 905 trial and B15 trial, just a minority of patients were able to conclude the EV Pembroke combination adjuvantly. So, in reality, already in real world, the EV Pembroke is not very much used in the adjuvant part. So, in actual, de-escalation is already happening. So, it would be interesting to see how the physician will absorb the EV durva paradigm with regards to their current use of EV Pembro and their current view on the continuation of therapy with EV Pembro in real world.

YL: Because, in my experience, the patients are reluctant to receive the adjuvant phases, because they receive the neoadjuvant part, and then surgery, and they are fed up with the numbers of visits that we have to give in the adjuvant phases. So, when you discuss with the patients, it's very tough to convince them that the adjuvant phases is very important. So, the VOLGA trial suggests that maybe we can remove this, and they will be happy, actually, to improve their quality of life.

FGR: In my opinion, there's also a relevant question remaining here is we have all these new therapies with excellent results, and we're speaking about de-escalating or de-intensifying the therapy, but we do not have any tools to select or to see which patients will not need more therapy and avoid toxicity, also financial toxicity, for those patients. So, what do you think, or how do you think, could we select some patients for de-intensification of that therapy?

YL: So, for the adjuvant phases, you mean?

FGR: Yeah.

YL: So, there is some initiative that tries to base the decision, I would say, on the PCR, but we discussed that maybe it's not so good. The other option is to base on ctDNA. So, we have some ctDNA data in B15, for example, in VOLGA, but it does not indicate whether or not we should de-escalate if you have a negative ctDNA. We know that the prognostic is better, but how much we can de-escalate, we don't know. So, that's, I think, an important research question for the academic group, for example. The main problem, the technologies that we have to use, so everything was based on Signatera.

So, we have seen that the whole genome sequencing-based tool is maybe more sensitive. So, that's like a concern that we have to find before we develop, actually, this de-escalation strategy.

AN: In principle, I would not focus the de-escalation issue only to the adjuvant part, but possibly to the neoadjuvant part. The 905 trial demonstrated that there is a group of patients, a sizable group of patients, that could benefit with pembrolizumab alone, neo-adjuvantly and adjuvantly, 25% response rate, which is in line with chemotherapy response rates. So, there is an opportunity here, an underlying opportunity also, to de-escalate the entire therapeutic pathway for these patients, and we need to invest more on this.

BS: Absolutely. Now, finally, I wanted to talk about the metastatic setting. That was a very interesting triplet clinical trial.

YL: Yeah, it's the future, actually. So, the standard of care is the EV-P, but now, more and more, we try to improve again, because there are some patients who develop primary resistance and secondary resistance, and so one strategy is to add another therapy. So, what kind of therapy could be another ADC, like Sacituzumab Govitecan, so the TRIP2 ADC, and we have this data from TROPHY, phase one trial, that combined EV-SG and a PD-1 inhibitor, avelumab and we have seen very good response rate, at least. So, 80% of response. So, it's a big difference, actually, for EV-P. The problem is how we can manage the toxicity, because, of course, if you had a new drug, and specifically ADC, you expect more toxicity, and to remind everyone that the trial was conducted in the context of phase one, so a very selected centre. So, before we move to big phase three trial, we have to maybe educate a lot of physicians in the context of big phase three trial, but at least the data are very interesting.

BS: Amazing. Well, thank you so much to all of you for being here and sharing your comments and thoughts, and thank you so much to all of you out there who are watching us and spending this time with us. Thank you.

Related Videos

Darolutamide plus ADT and radiotherapy improves metastasis free survival in very high risk prostate cancer

Dr Tamim Niazi - McGill University, Montreal, Canada
Darolutamide plus ADT and radiotherapy improves metastasis free survival in very high risk prostate cancer ( Dr Tamim Niazi - McGill University, Montreal, Canada )
26 Oct 2026

Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC

Dr Neeraj Agarwal - University of Utah, Salt Lake City, USA
Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC ( Dr Neeraj Agarwal - University of Utah, Salt Lake City, USA )
9 Jun 2026

177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC

Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA
177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC ( Dr Pedro Barata - University Hospitals Seidman Cancer Center, Cleveland, USA )
1 Jun 2026

Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC

Dr David Pook - Monash Health, Melbourne, Australia
Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC ( Dr David Pook - Monash Health, Melbourne, Australia )
1 Jun 2026

Cabozantinib plus nivolumab and ipilimumab shows promising brain metastasis control in advanced kidney cancer

Dr Jianbo Wang - MD Anderson Cancer Center, Houston, USA
Cabozantinib plus nivolumab and ipilimumab shows promising brain metastasis control in advanced kidney cancer ( Dr Jianbo Wang - MD Anderson Cancer Center, Houston, USA )
18 Mar 2026

Circulating tumour DNA dynamics predict outcomes with pembrolizumab in advanced kidney cancer

Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA
Circulating tumour DNA dynamics predict outcomes with pembrolizumab in advanced kidney cancer ( Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA )
18 Mar 2026

Latest in bladder cancer from the second half of 2025

Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone and Dr Enrique Grande
Latest in bladder cancer from the second half of 2025 ( Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone and Dr Enrique Grande )
25 Nov 2025

Bladder cancer updates from the first half of 2025

Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone and Dr Benjamin Pradere
Bladder cancer updates from the first half of 2025 ( Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone and Dr Benjamin Pradere )
26 Sep 2025

EAU 2025: Updates in NMIBC

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Alexandra Masson-Lecomte and Dr Giuseppe Simone
EAU 2025: Updates in NMIBC ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Alexandra Masson-Lecomte and Dr Giuseppe Simone )
25 Mar 2025